ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

バイオ製品Bio Products

タンパク質(癌免疫療法用)

ACROBiosystems社 プロダクトリスト:Recombinant Protein

サプライヤー
AcroBioSystems
カタログNo.
RAL-H5240
製品名称
Human TNFSF11 / RANKL / CD254 Protein, His tag
タンパク質名
TNFSF11
Species
Human
HOST
HEK293
50ug: 74,000円
お問い合わせ

Overview

Synonyms RANKL,CD254,TRANCE,OPGL,ODF
Characteristics This protein carries a polyhistidine tag at the N-terminus. The protein has a calculated MW of 23.1 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level Less than 1.0 EU per μg by the LAL method.
Purity >95% as determined by SDS-PAGE.
Description Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.
Reference (1) Hanada R., et al., 2011, J. Mol. Med. 89 (7): 647-656.
(2) Findlay DM., et al., 2011, Osteoporos Int. 22 (10): 2597-2602.
(3) Schmiedel BJ., et al., 2013, Cancer Res. 73 (2): 683-694.
(4) Castellano D., et al., 2011, Oncologist. 16 (2): 136-145.
URL https://www.acrobiosystems.com/P2374-Human-TNFSF11--RANKL--CD254--TRANCE-Protein-His-tag.html

お問い合わせリスト(-)

お問い合わせフォーム